Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 1;46(2):e78-e79.
doi: 10.1097/RLU.0000000000003245.

Widespread Metastatic Gastric Signet-Ring Cell Carcinoma Shown by 68Ga-FAPI PET/CT

Chunlei Fan  1 , Wei Guo  2 , Guoqiang Su  1 , Bo Chen  1 , Haojun Chen  2
Affiliations

Widespread Metastatic Gastric Signet-Ring Cell Carcinoma Shown by 68Ga-FAPI PET/CT

Chunlei Fan et al. Clin Nucl Med. .

Abstract

The present study compared 68Ga-FAPI and 18F-FDG PET/CT in a patient with GSRCC (gastric signet-ring cell carcinoma). In this case, 68Ga-FAPI PET/CT shows much higher tumor-to-background contrast of primary tumor and reveals more metastatic lesions than 18F-FDG PET/CT. This case demonstrates that 68Ga-FAPI PET/CT outperforms 18F-FDG in identifying both primary and metastatic lesions in GSRCC.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest and sources of funding: The authors declare no conflicts of interest. This work was supported by the National Natural Science Foundation of China (grant no. 81801735 and grant no. 81701736).

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bhure U, Schmitt AM, Pestalozzi BC, et al. FDG-negative signet ring cell cancer of the stomach with FDG-positive skin metastases. Clin Nucl Med . 2007;32:226–228.
    1. Buyyounouski MK, Klump WJ, Konski A, et al. FDG PET imaging of signet-ring cell adenocarcinoma of the stomach. Clin Nucl Med . 2005;30:118–119.
    1. Yoshioka T, Yamaguchi K, Kubota K, et al. Evaluation of 18 F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med . 2003;44:690–699.
    1. Chen H, Pang Y, Wu J, et al. Comparison of [ 68 Ga]Ga-DOTA-FAPI-04 and [ 18 F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging . 2020;47:1820–1832.
    1. Giesel FL, Kratochwil C, Lindner T, et al. 68 Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med . 2019;60:386–392.

MeSH terms